AACR21: personalized cancer vaccine is safe and exhibits potential benefit

Results from a Phase I clinical trial, presented at the American Association for Cancer Research Annual Meeting (AACR; 9–14 April 2021), have demonstrated that a personalized cancer vaccine is both safe and exhibits potential benefit for those cancers that have a high risk of recurrence. Patients enrolled in the trial received 10 doses of a personalized vaccine over a 6-month period, after they had undergone their standard cancer treatment. In order to create the personalized vaccines, the team of researchers from Icahn School of Medicine at Mount Sinai (NY, USA), sequenced each patients tumor and germline DNA as well as...